If we took this issue into consideration and assumed that every non-squamous NSCLC patient received pemetrexed maintenance therapy after pemetrexed plus carboplatin, the ICERs of N+I versus chemotherapy for all patients, patients with PD-L1 ≥ 1%, and patients with PD-L1 < 1% would become $212,823, $220,670, and $200,814 per QALY, respectively, which were still higher than the willingness-to-pay threshold value. The gene discussed is CD274; the disease is non-small cell lung carcinoma.